NASPGHAN POLICY REGARDING MEMBERS FROM INDUSTRY/PHARMA SERVING ON NASPGHAN COMMITTEES

The Ethics Committee appreciates the contribution of industry to the annual meeting as well as other symposia, and recognizes the value of ideas outside that of academia and private practice. NASPGHAN is concerned about the influence of industry on a not for profit society such as NASPGHAN, however. In order to allow these individuals the potential to contribute to NASPGHAN Committees without conflict of interest, the following policy has been developed which creates a committee liaison status for members employed by industry/pharma, assuring that they are non-voting, and adhere to the following guidelines:

- A NASPGHAN member employed directly by pharma/industry cannot serve as Chair or Co-Chair of a NASPGHAN committee.

- A NASPGHAN member employed directly by pharma/industry cannot serve as a voting member of a committee.

- A NASPGHAN member employed directly by pharma/industry may apply to serve on the following committees as a liaison, as long as pharma/industry membership is less than 10% of the specific committee.
  - Endoscopy and Procedures, Professional Education, Public Education; Training; Professional Development, IBD, Nutrition, Pancreas, Hepatology, Neurogastroenterology/Motility and International Committees, Technology

- A NASPGHAN member employed directly by pharma/industry cannot serve on the following committees. Whether real or perceived, the conflict of interest present in these committees precludes members receiving significant compensation through industry from serving on the following committees:
  - Awards, Clinical Care and Quality, Clinical Practice, Ethics, Fellows, Finance, Nominations, Affairs/Advocacy, Publications, and Research, Committees.

- NASPGHAN members employed directly by pharma/industry should not comprise more than ~10% of a committee’s membership.

- NASPGHAN special interest groups fall outside these guidelines and offer an opportunity for members in industry to share ideas and opinions within these groups.

- Adherence to the COI Policy is expected for those with pharma/industry relationships.

Adopted by the NASPGHAN Council 2019